NASDAQ:EFTR eFFECTOR Therapeutics (EFTR) Stock Price, News & Analysis $0.05 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.05▼$0.0550-Day Range$0.04▼$1.9452-Week Range$0.03▼$20.50Volume24,737 shsAverage Volume452,466 shsMarket Capitalization$216,200.00P/E RatioN/ADividend YieldN/APrice Target$24.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get eFFECTOR Therapeutics alerts: Email Address eFFECTOR Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside52,073.9% Upside$24.00 Price TargetShort InterestBearish16.84% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.76 out of 5 stars 3.5 Analyst's Opinion Consensus RatingeFFECTOR Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageeFFECTOR Therapeutics has received no research coverage in the past 90 days.Read more about eFFECTOR Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted16.84% of the float of eFFECTOR Therapeutics has been sold short.Short Interest Ratio / Days to CovereFFECTOR Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in eFFECTOR Therapeutics has recently increased by 650.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldeFFECTOR Therapeutics does not currently pay a dividend.Dividend GrowtheFFECTOR Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EFTR. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for EFTR on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, eFFECTOR Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.70% of the stock of eFFECTOR Therapeutics is held by insiders.Percentage Held by Institutions57.67% of the stock of eFFECTOR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about eFFECTOR Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of eFFECTOR Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of eFFECTOR Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about eFFECTOR Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monument Traders AllianceThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... In fact, it just detected a move happening this MONDAY.See here to see the full details. About eFFECTOR Therapeutics Stock (NASDAQ:EFTR)eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.Read More EFTR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EFTR Stock News HeadlinesJuly 15, 2024 | investorplace.com3 Publicly Traded Companies Filing for Bankruptcy as July Kicks OffJune 24, 2024 | globenewswire.comeFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from NasdaqJuly 26, 2024 | Paradigm Press (Ad)Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.May 20, 2024 | globenewswire.comeFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian CancerMay 9, 2024 | investorplace.comEFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024May 9, 2024 | globenewswire.comeFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 9, 2024 | globenewswire.comeFFECTOR Therapeutics to Participate in Upcoming Investor ConferenceApril 4, 2024 | marketwatch.comEFFECTOR Therapeutics Shares Drop as Development of Lung Cancer Treatment Drug EndsJuly 26, 2024 | Paradigm Press (Ad)Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.April 4, 2024 | markets.businessinsider.comEFFECTOR Reports Results Of Phase2 KICKSTART Trial Of Tomivosertib-Pembrolizumab In NSCLCApril 4, 2024 | finance.yahoo.comCancer-Focused eFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing DataApril 4, 2024 | globenewswire.comeFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung CancerMarch 28, 2024 | markets.businessinsider.comBuy Rating for eFFECTOR Therapeutics Backed by Solid Financials and Promising Zotatifin TrialsMarch 27, 2024 | finanznachrichten.deeFFECTOR Therapeutics, Inc.: eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 25, 2024 | investorplace.comEFTR Stock Earnings: eFFECTOR Therapeutics Misses EPS for Q4 2023March 25, 2024 | globenewswire.comeFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: eFFECTOR Therapeutics (EFTR), Apellis Pharmaceuticals (APLS) and Ultragenyx Pharmaceutical (RARE)February 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for eFFECTOR Therapeutics Amid Promising Oncology Drug Milestones and Extended Financial RunwaySee More Headlines Receive EFTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for eFFECTOR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EFTR CUSIPN/A CIK1828522 Webwww.locustwalkacquisitioncorp.com Phone858-925-8215FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$24.00 High Stock Price Target$24.00 Low Stock Price Target$24.00 Potential Upside/Downside+52,073.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($13.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,810,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-146.23% Debt Debt-to-Equity RatioN/A Current Ratio1.03 Quick Ratio1.03 Sales & Book Value Annual Sales$3.55 million Price / Sales0.06 Cash FlowN/A Price / Cash FlowN/A Book Value($1.94) per share Price / Book-0.02Miscellaneous Outstanding Shares4,700,000Free Float4,483,000Market Cap$216,200.00 OptionableNo Data Beta0.62 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Stephen T. Worland Ph.D. (Age 66)CEO, President & Director Comp: $873.96kMr. Michael Byrnes M.B.A. (Age 47)Chief Financial Officer Comp: $654.82kDr. Douglas Warner M.D. (Age 52)Chief Medical Officer Comp: $660.16kDr. Davide Ruggero Ph.D.Co-Founder and Member of Clinical & Scientific Advisory BoardDr. Kevan M. Shokat Ph.D.Co-Founder and Member of Clinical & Scientific Advisory BoardKey CompetitorsBiodexa PharmaceuticalsNASDAQ:BDRXHistogenNASDAQ:HSTOAkandaNASDAQ:AKANAmpio PharmaceuticalsNYSE:AMPELucy Scientific DiscoveryNASDAQ:LSDIView All CompetitorsInsiders & InstitutionsBlackstone Inc.Sold 1,256,244 shares on 5/16/2024Ownership: 1.419%StemPoint Capital LPBought 132,793 shares on 5/14/2024Ownership: 3.599%Carlyle Group Inc.Sold 4,629,230 shares on 5/3/2024Ownership: 5.227%Sr One Capital Management, LlcSold 24,366 sharesTotal: $371,581.50 ($15.25/share)View All Insider TransactionsView All Institutional Transactions EFTR Stock Analysis - Frequently Asked Questions How have EFTR shares performed this year? eFFECTOR Therapeutics' stock was trading at $11.6850 at the beginning of 2024. Since then, EFTR stock has decreased by 99.6% and is now trading at $0.0460. View the best growth stocks for 2024 here. How were eFFECTOR Therapeutics' earnings last quarter? eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) released its quarterly earnings results on Thursday, May, 9th. The company reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.17) by $0.01. When did eFFECTOR Therapeutics' stock split? eFFECTOR Therapeutics shares reverse split on Friday, January 12th 2024. The 1-25 reverse split was announced on Friday, January 12th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of eFFECTOR Therapeutics? Shares of EFTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EFTR) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eFFECTOR Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eFFECTOR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EFTR Stock Alerts